A March 2025 study by researchers at the University of Pennsylvania found 85% people on GLP-1s scored worse on a Waterless Empirical Taste Test, which involved touching flavored plastic strips to their tongues, compared to people not on the drugs
For patients & payers: A step toward lower costs and broader access to proven obesity treatments For Teva Pharmaceuticals: A strategic move into one of the fastest-growing segments in global pharma For Novo Nordisk: Limited short-term impact, but mounting competitive pressure as generics gain ground This development could reshape affordability, accessibility, and competition in obesity care signaling the beginning of a new chapter for patients and healthcare systems worldwide
The combination of fiber, healthy fats, and lean protein creates multiple opportunities for nutrient-stimulated hormone responses throughout the day
Achieve radiant, glowing skin with the Skin Brightening IV Drip at House of Aesthetics Bromley
Lodish MB
Existing Medicare Part D coverage for Ozempic when prescribed for Type 2 diabetes remains separate from the Medicare GLP-1 Bridge